| Variables | Obese (n = 38) | Non-obese (n = 52) | P-value | |
| Age | 53.1 ± 15.1 | 56.8 ± 11.6 | 0.21 | |
| Female gender | 23 (60.5%) | 28 (53.8%) | 0.53 | |
| ASA grade | 2 | 3 (8.6%) | 7 (13.5%) | 0.78 |
| 3 | 25 (71.4%) | 37 (71.2%) | ||
| 4 | 7 (20%) | 8 (15.4%) | ||
| BMI | 34.5 (31.6 - 39.7) | 25.3 (22.7 - 27.9) | <0.01 | |
| ECOG scale | 0 | 19 | 28 | 0.69 |
| 1 | 17 | 18 | ||
| 2 | 2 | 5 | ||
| 3 | 0 | 1 | ||
| Previous abdominal surgery | 10 (26.3%) | 28 (53.8%) | 0.01 | |
| Previous liver resection | 2 (5.3%) | 6 (11.5%) | 0.46 | |
| Smoking | Current/former | 17 (44.7%) | 32 (61.5%) | 0.17 |
| Never | 21 (55.3%) | 20 (38.5%) | ||
| Alcohol | 22 (57.9%) | 26 (50%) | 0.52 | |
| Cirrhosis | 3 (7.9%) | 11 (21.2%) | 0.09 | |
| Albumin (pre-operative) | 4.0 (3.8 - 4.2) | 4.1 (3.75 - 4.2) | 0.66 | |
| T.Bilirubin (pre-operative) | 0.6 (0.325 - 0.70) | 0.6 (0.4 - 0.9) | 0.08 | |
| Vascular involvement | 1 (3.3%) | 1 (2.0%) | 1.00 | |
| Neoadjuvant therapy | 7 (18.4%) | 13 (25%) | 0.61 | |
| Malignant diagnosis | 16 (42.1%) | 38 (73.1%) | <0.01 | |